[1] Xia CF, Dong XS, Li H, et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.   doi: 10.1097/CM9.0000000000002108
[2] Cellini M, Rotondi M, Tanda ML, et al.  Skeletal health in patients with differentiated thyroid carcinoma[J]. J Endocrinol Invest, 2021, 44(3): 431-442.   doi: 10.1007/s40618-020-01359-6
[3]

李继承, 曾园山. 组织学与胚胎学[M]. 9版. 北京: 人民卫生出版社, 2018: 27−30.

Li JC, Zeng YS. Histology and embryology[M]. 9th ed. Beijing: People's Medical Publishing House, 2018: 27−30.
[4]

Gouveia CHA, Miranda-Rodrigues M, Martins GM, et al. Thyroid hormone and skeletal development[J/OL]. Vitam Horm, 2018, 106: 383−472[2022-02-21]. https://www.sciencedirect.com/science/article/abs/pii/S0083672917300407?via%3Dihub. DOI: 10.1016/bs.vh.2017.06.002.
[5] Bassett JHD, Williams GR.  Role of thyroid hormones in skeletal development and bone maintenance[J]. Endocr Rev, 2016, 37(2): 135-187.   doi: 10.1210/er.2015-1106
[6] Bassett JHD, Boyde A, Howell PGT, et al.  Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts[J]. Proc Natl Acad Sci USA, 2010, 107(16): 7604-7609.   doi: 10.1073/pans.0911346107
[7] Arnautovic-Halimic A, Begic A, Agic-Bilalagic S, et al.  Evaluation of thyroid hormone status and bone density ratio in euthyroid postmenopausal women in early and late stage of bone loss[J]. Mater Sociomed, 2019, 31(2): 115-118.   doi: 10.5455/msm.2019.31.115-118
[8] Abe E, Marians RC, Yu WQ, et al.  TSH is a negative regulator of skeletal remodeling[J]. Cell, 2003, 115(2): 151-162.   doi: 10.1016/s0092-8674(03)00771-2
[9] Williams GR.  Extrathyroidal expression of TSH receptor[J]. Ann Endocrinol (Paris), 2011, 72(2): 68-73.   doi: 10.1016/j.ando.2011.03.006
[10] Ma RS, Morshed S, Latif R, et al.  The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis[J]. Thyroid, 2011, 21(8): 897-906.   doi: 10.1089/thy.2010.0457
[11] Sampath TK, Simic P, Sendak R, et al.  Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats[J]. J Bone Miner Res, 2007, 22(6): 849-859.   doi: 10.1359/jbmr.070302
[12]

Deng T, Zhang WW, Zhang YL, et al. Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation[J/OL]. BMC Endocr Disord, 2021, 21(1): 49[2022-02-21]. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-021-00715-8. DOI: 10.1186/s12902-021-00715-8.
[13] Du BH, Du FM, Liu Y, et al.  Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy[J]. Endokrynol Pol, 2020, 71(1): 15-20.   doi: 10.5603/EP.a2019.0049
[14] Ku EJ, Yoo WS, Lee EK, et al.  Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106(12): 3655-3667.   doi: 10.1210/clinem/dgab539
[15] Papaleontiou M, Banerjee M, Reyes-Gastelum D, et al.  Risk of osteoporosis and fractures in patients with thyroid cancer: a case-control study in U.S. veterans[J]. Oncologist, 2019, 24(9): 1166-1173.   doi: 10.1634/theoncologist.2019-0234
[16] Mendonça Monteiro de Barros G, Madeira M, Vieira Neto L, et al.  Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients[J]. J Bone Miner Metab, 2016, 34(4): 417-421.   doi: 10.1007/s00774-015-0680-4
[17] Wang LY, Smith AW, Palmer FL, et al.  Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma[J]. Thyroid, 2015, 25(3): 300-307.   doi: 10.1089/thy.2014.0287
[18] Tournis S, Antoniou JD, Liakou CG, et al.  Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression[J]. Clin Endocrinol (Oxf), 2015, 82(2): 197-204.   doi: 10.1111/cen.12560
[19]

Chung CW, Choi HS, Kong SH, et al. Measurements of bone health after thyroid-stimulating suppression therapy in postmenopausal women with differentiated thyroid carcinoma: bone mineral density versus the trabecular bone score[J/OL]. J Clin Med, 2021, 10(9): 1964[2022-02-21]. https://www.mdpi.com/2077-0383/10/9/1964. DOI: 10.3390/jcm10091964.
[20] Sousa BÉCA, Silva BC, de Oliveira Guidotti T, et al.  Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy[J]. J Endocrinol Invest, 2021, 44(10): 2295-2305.   doi: 10.1007/s40618-021-01537-0
[21]

Hawkins Carranza F, Guadalix Iglesias S, Luisa De Mingo Domínguez M, et al. Trabecular bone deterioration in differentiated thyroid cancer: impact of long-term TSH suppressive therapy[J/OL]. Cancer Med, 2020, 9(16): 5746−5755[2022-02-21]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.3200. DOI: 10.1002/cam4.3200.
[22] De Mingo Dominguez ML, Guadalix Iglesias S, Martin-Arriscado Arroba C, et al.  Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy[J]. Endocrine, 2018, 62(1): 166-173.   doi: 10.1007/s12020-018-1671-8
[23] 中华医学会骨质疏松和骨矿盐疾病分会.  原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志, 2019, 25(3): 281-309.   doi: 10.3969/j.issn.1006-7108.2019.03.001
Chinese Society of Osteoporosis and Bone Mineral Research.  Guidelines for the diagnosis and management of primary osteoporosis (2017)[J]. Chin J Osteoporos, 2019, 25(3): 281-309.   doi: 10.3969/j.issn.1006-7108.2019.03.001
[24] 中国定量CT(QCT)骨质疏松症诊断指南工作组, 程晓光, 王亮, 等.  中国定量CT(QCT)骨质疏松症诊断指南(2018)[J]. 中国骨质疏松杂志, 2019, 25(6): 733-737.   doi: 10.3969/j.issn.1006-7108.2019.06.001
The Committee for the China Guideline for the Diagnosis Criteria of Osteoporosis with Quantitative Computed Tomography, Cheng XG, Wang L, et al.  The China guideline for the diagnosis criteria of osteoporosis with quantitative computed tomography (QCT) (2018)[J]. Chin J Osteoporos, 2019, 25(6): 733-737.   doi: 10.3969/j.issn.1006-7108.2019.06.001
[25] Lee Y, Yoon BH, Lee S, et al.  Risk of osteoporotic fractures after thyroid-stimulating hormone suppression therapy in patients with thyroid cancer[J]. J Bone Metab, 2019, 26(1): 45-50.   doi: 10.11005/jbm.2019.26.1.45
[26] Biondi B, Cooper DS.  Thyroid hormone suppression therapy[J]. Endocrinol Metab Clin North Am, 2019, 48(1): 227-237.   doi: 10.1016/j.ecl.2018.10.008
[27] Mazziotti G, Formenti AM, Frara S, et al.  High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2018, 103(3): 956-964.   doi: 10.1210/jc.2017-01986
[28] Shevroja E, Cafarelli FP, Guglielmi G, et al.  DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis[J]. Endocrine, 2021, 74(1): 20-28.   doi: 10.1007/s12020-021-02806-x
[29] Fu Y, Li C, Luo W, et al.  Fragility fracture discriminative ability of radius quantitative ultrasound: a systematic review and meta-analysis[J]. Osteoporos Int, 2021, 32(1): 23-38.   doi: 10.1007/s00198-020-05559-x
[30] 屈晓龙, 蒋涛, 曹宗锐, 等.  骨转换标志物与骨密度预测老年女性骨质疏松性骨折的对比研究[J]. 中国骨质疏松杂志, 2020, 26(1): 31-36.   doi: 10.3969/j.issn.1006-7108.2020.01.008
Qu XL, Jiang T, Cao ZR, et al.  Comparative study of bone turnover markers and bone mineral density in prediction of osteoporotic fractures in the elder women[J]. Chin J Osteoporos, 2020, 26(1): 31-36.   doi: 10.3969/j.issn.1006-7108.2020.01.008
[31]

Tian AX, Ma JX, Feng KQ, et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis[J/OL]. J Orthop Surg Res, 2019, 14(1): 68[2022-02-21]. https://josr-online.biomedcentral.com/articles/10.1186/s13018-019-1100-6. DOI: 10.1186/s13018-019-1100-6.
[32] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[33] 中国临床肿瘤学会指南工作委员会.  中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1200.   doi: 10.3969/j.issn.1674-0904.2021.12.013
Guidelines Working Committee of Chinese Society of Clinical Oncology.  Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer[J]. J Cancer Control Treat, 2021, 34(12): 1164-1200.   doi: 10.3969/j.issn.1674-0904.2021.12.013
[34] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
Chinese Society of Nuclear Medicine.  Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
[35] Panico A, Lupoli GA, Fonderico F, et al.  Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate[J]. Thyroid, 2009, 19(5): 437-442.   doi: 10.1089/thy.2008.0428
[36] Schneider DL, Barrett-Connor EL, Morton DJ.  Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen[J]. JAMA, 1994, 271(16): 1245-1249.   doi: 10.1001/jama.271.16.1245
[37]

Kim Y, Tian YX, Yang JX, et al. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis[J/OL]. Sci Rep, 2020, 10(1): 11115[2022-02-21]. https://www.nature.com/articles/s41598-020-68037-8. DOI: 10.1038/s41598-020-68037-8.
[38] Lyu H, Jundi B, Xu C, et al.  Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials[J]. J Clin Endocrinol Metab, 2019, 104(5): 1753-1765.   doi: 10.1210/jc.2018-02236
[39] Kendler DL, Marin F, Zerbini CAF, et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial[J]. Lancet, 2018, 391(10117): 230-240.   doi: 10.1016/S0140-6736(17)32137-2